![](/images/graphics-bg.png)
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
Joint Authors
Panda, Sanjib kumar
Nirvanashetty, Somashekara
Parachur, Vivek A.
Mohanty, Nilima
Swain, Tathastu
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-10-25
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Curene® is a bioavailable formulation of turmeric Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology.
Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme and hence have potential application in the treatment of Osteoarthritis (OA).
To evaluate the safety and efficacy of Curene® a randomized, double blind, placebo controlled, parallel-group study was conducted in subjects with knee OA.
Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile.
Methods.
Fifty (50) subjects aged between 40 and 75 years who were suffering from unilateral or bilateral OA of the knee for greater than 3 months according to American College of Rheumatology (ACR) criteria were enrolled.
They were randomized into two treatment groups; one group received Curene® 500 mg once daily and the other group received placebo.
Efficacy was evaluated using change from baseline in Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.
Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of Curene® in OA patients.
Result.
Forty-six (46) subjects completed the study.
The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo.
It was also found to be safe and well tolerated as there was no incidence of treatment related AEs.
Conclusion.
Curene® results in statistically significant and clinically meaningful reduction in pain, stiffness, and improvement in physical functioning in subjects suffering from knee OA.
Curene® also demonstrates excellent safety profile during the study.
Trial Registration.
This trial is registered with Clinical Trial Registry, India, CTRI/2017/07/009044, registered on 14th July 2017, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19264&EncHid=&userName=ocius%20life%20sciences.
American Psychological Association (APA)
Panda, Sanjib kumar& Nirvanashetty, Somashekara& Parachur, Vivek A.& Mohanty, Nilima& Swain, Tathastu. 2018. A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA. BioMed Research International،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1127205
Modern Language Association (MLA)
Panda, Sanjib kumar…[et al.]. A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA. BioMed Research International No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1127205
American Medical Association (AMA)
Panda, Sanjib kumar& Nirvanashetty, Somashekara& Parachur, Vivek A.& Mohanty, Nilima& Swain, Tathastu. A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1127205
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1127205